A Novel Agent Targeting APRIL: A New Hope for Elderly Patients of IgA Nephropathy

Overview

Journal Aging Med (Milton)

Specialty Geriatrics

Date 2025 Feb 14

PMID 39949470

Authors

Xin Liu

Li Zuo

Affiliations

Soon will be listed here.

Abstract

Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes the activity of APRIL. It should usher in a new era in the treatment of IgAN, especially in elderly patients.

References

Pattrapornpisut P, Avila-Casado C, Reich H . IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021; 78(3):429-441. DOI: 10.1053/j.ajkd.2021.01.024. View

Fellstrom B, Barratt J, Cook H, Coppo R, Feehally J, De Fijter J . Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017; 389(10084):2117-2127. DOI: 10.1016/S0140-6736(17)30550-0. View

Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M . After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020; 98(4):1044-1052. DOI: 10.1016/j.kint.2020.04.046. View

Song Y, Cai G, Xiao Y, Wang Y, Yuan B, Xia Y . Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol. 2017; 18(1):61. PMC: 5307812. DOI: 10.1186/s12882-017-0467-z. View

Hou J, Le W, Chen N, Wang W, Liu Z, Liu D . Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial. Am J Kidney Dis. 2017; 69(6):788-795. DOI: 10.1053/j.ajkd.2016.11.027. View

Kiryluk K, Sanchez-Rodriguez E, Zhou X, Zanoni F, Liu L, Mladkova N . Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet. 2023; 55(7):1091-1105. PMC: 11824687. DOI: 10.1038/s41588-023-01422-x. View

Wheeler D, Toto R, Stefansson B, Jongs N, Chertow G, Greene T . A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021; 100(1):215-224. DOI: 10.1016/j.kint.2021.03.033. View

Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B . Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. J Am Soc Nephrol. 2017; 29(1):317-325. PMC: 5748925. DOI: 10.1681/ASN.2017060713. View

Liu L, Yang Y, Shi S, Bao Y, Yang C, Zhu S . Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis. 2019; 74(1):15-22. DOI: 10.1053/j.ajkd.2019.01.026. View

10.

Heerspink H, Radhakrishnan J, Alpers C, Barratt J, Bieler S, Diva U . Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023; 401(10388):1584-1594. DOI: 10.1016/S0140-6736(23)00569-X. View

11.

Mathur M, Barratt J, Chacko B, Chan T, Kooienga L, Oh K . A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. N Engl J Med. 2023; 390(1):20-31. PMC: 7615905. DOI: 10.1056/NEJMoa2305635. View

12.

Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J . Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2022; 103(2):391-402. DOI: 10.1016/j.kint.2022.09.017. View

13.

Cheung C, Barratt J, Carroll K, Lafayette R, Liew A, Suzuki Y . Targeting APRIL in the Treatment of IgA Nephropathy. Clin J Am Soc Nephrol. 2023; 19(3):394-398. PMC: 10937009. DOI: 10.2215/CJN.0000000000000338. View

14.

Sarcina C, Tinelli C, Ferrario F, Pani A, De Silvestri A, Scaini P . Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. Clin J Am Soc Nephrol. 2016; 11(6):973-981. PMC: 4891742. DOI: 10.2215/CJN.02300215. View

15.

Lv J, Wong M, Hladunewich M, Jha V, Hooi L, Monaghan H . Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022; 327(19):1888-1898. PMC: 9115617. DOI: 10.1001/jama.2022.5368. View

16.

. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021. View